Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10014901 | 0.75 | ALDH1A1 (0.44) | ALDH1A1MAPK14DOT1LMEN1KMT2A | |
| SCHEMBL7101680 | 0.74 | KMT2A (0.51) | ALDH1A1DOT1LMEN1KMT2ACASP1 | |
| SCHEMBL10014904 | 0.74 | ALDH1A1 (0.43) | ALDH1A1EGLN1HTTALOX15RAB9A | |
| SCHEMBL9360254 | 0.74 | MEN1 (0.55) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL29977567 | 0.74 | MEN1 (0.55) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL1145034 | 0.72 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL29406417 | 0.72 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL2232014 | 0.70 | ALDH1A1 (0.55) | ALDH1A1DOT1LMEN1KMT2ACASP1 | |
| SCHEMBL2524478 | 0.70 | ALDH1A1 (0.55) | ALDH1A1DOT1LMEN1KMT2ACASP1 | |
| SCHEMBL4517996 | 0.70 | ALDH1A1 (0.55) | ALDH1A1DOT1LMEN1KMT2ACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2296655-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009140138-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2008088937-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008088937-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | ALDH1A1 899/4885MAPK14 4051/4885DOT1L 1668/4885 |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ADRA2C, ADRA2B, ADRB3 | ALDH1A1 1423/4885MAPK14 3082/4885DOT1L 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.